- Clinically proven to reduce pigmentation, dark spots and stubborn brown spots(1-7)
- The most tested cysteamine-based product in clinical trials (1-7): over 200 subjects recruited, 7 peer-reviewed publications
- Helps reduce the size and intensity of dark spots and limit the appearance of new spots
- Strong antioxidant effect
- Easy to use - can be integrated into your daily skin care routine.
- Gentle on the skin and suitable for all skin types and ethnicities
- Can be used on different parts of the body
- Hydroquinone-free and safe for permanent, long-term use
- Well tolerated and safe to use in summer
- Can be combined with aesthetic procedures(8-9)
- Cruelty free and not tested on animals.
VISIBLE RESULTS
Depigmenting effects
- 80% of melanin synthesis by cysteamine, demonstrated in in vitro studies(10)
- 67% reduction in the intensity of dark spots after 16 weeks of Cyspera® (2)
- 100% of subjects achieved visible effects after 16 weeks according to the investigator(2)
- 92% of subjects noticed visible effects after 16 weeks(2)
(1) Hsu, C., Mahdi, HA, Pourahmadi, M., & Ahmadi, S. (2013, April). Cysteamine cream as a new skin depigmenting product. In Journal of the American Academy of Dermatology (Vol. 68, No. 4, pp. AB189-AB189). 360
(2) Mansouri P, Farshi S, Hashemi Z, Kasraee B (2015). Evaluation of the efficacy of cysteamine 5% cream in the treatment of epidermal melasma: a randomized double-blind placebo-controlled trial. Br J Dermatol, 173(1), 209-217
(3) Farshi S, Mansouri P, Kasraee B (2018). Efficacy of cysteamine cream in the treatment of epidermal melasma, evaluated by Dermacatch as a new measurement method: a randomized double-blind placebo-controlled study. J Dermatologist Treat, 29(2), 182-189.
(4) Karrabi M, David, J, Sahebkar M. (2020). Clinical evaluation of efficacy, safety and tolerability of cysteamine 5% cream in comparison with modified Kligman's formula in subjects with epidermal melasma: A randomized, double‐blind clinical trial study. Skin Res Technol.
(5). Kasraee B, Mansouri, P Farshi, S. (2019). Significant therapeutic response to cysteamine cream in a melasma patient resistant to Kligman's formula. J Cosmet Dermatol, 18(1), 293-295.
(6) Nguyen J, Remyn L, Chung IY, Honigman A, Gourani‐Tehrani S, Wutami I, Rodrigues M. (2021). Evaluation of the efficacy of cysteamine cream compared to hydroquinone in the treatment of melasma: A randomized, double‐blinded trial. Australas J Dermatol, 62(1), e41-e46. (7) Karrabi M, Mansournia MA, Sharestanaki E, Abdollahnejad Y, Sahebkar M. (2020). Clinical evaluation of efficacy and tolerability of cysteamine 5% cream in comparison with tranexamic acid mesotherapy in subjects with melasma: a single-blind, randomized clinical trial study. Arch of Dermatol Res, 1-9.
(8) Marini L., Prime Journal, 2019 May/June 70–73
(9) Johnson B. et al. “Novel Combination of a 650-Microsecond Neodymium-doped Yttrium Aluminum Garnet 1,064-nm Laser and Cysteamine Cream for the Treatment of Melasma: A Case Study.” J Clin Aesthet Dermatol. 2020;13(3):28–30
(10) Qui L. et al, J. Invest Dermatol. 2000 Jan;114(1):21-7
){kind=link}